NCT05054725 2026-01-06
Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies
Revolution Medicines, Inc.
Phase 2 Completed
Revolution Medicines, Inc.
SWOG Cancer Research Network
M.D. Anderson Cancer Center
Fundación GECP
Vestre Viken Hospital Trust